Pancreatic Cancer Research

ResearcherKumamoto Regional Medical CenterActive in the last 2 years

Takayoshi Kaida

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9134-6124; OpenAlex author ID A5101735337, A5108542571. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2016: 3 papers · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper

Papers 10

  1. Impairment of perioperative activities of daily living is associated with poor prognosis following pancreatectomy for pancreatic cancer. Last author DOI 10.1007/s00423-024-03478-7↗
  2. The Prognostic Role of Serine Racemase in Patients With Pancreatic Cancer: A New Marker in Cancer Metabolism. Co-author DOI 10.1097/mpa.0000000000002210↗
  3. Thrombospondin-1 overexpression stimulates loss of Smad4 and accelerates malignant behavior via TGF-β signal activation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2022.101533↗
  4. Survival Impact of Perioperative Red Blood Cell Transfusion During Pancreatectomy in Patients With Pancreatic Ductal Adenocarcinoma: A Propensity Score Matchin… Co-author DOI 10.1097/mpa.0000000000001997↗
  5. High Expression of Bloom Syndrome Helicase is a Key Factor for Poor Prognosis and Advanced Malignancy in Patients with Pancreatic Cancer: A Retrospective Study. Co-author DOI 10.1245/s10434-022-11500-9↗
  6. Frailty is associated with poor prognosis after resection for pancreatic cancer. Co-author DOI 10.1007/s10147-021-01983-z↗
  7. Multiple Primary Cancers in Patients with Pancreatic Cancer. Co-author DOI 10.1177/000313481808401205↗
  8. Intraoperative blood loss is not a predictor of prognosis for pancreatic cancer. Co-author DOI 10.1007/s00595-015-1238-8↗
  9. The diagnostic role of the neutrophil-to-lymphocyte ratio in predicting pancreatic ductal adenocarcinoma in patients with pancreatic diseases. Co-author DOI 10.1007/s10147-016-0975-z↗
  10. Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000624↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiromitsu Hayashi · 7 shared papers, 2016–2024 · strength 0.96
  2. Shigeki Nakagawa · 6 shared papers, 2018–2024 · strength 0.83
  3. Katsunori Imai · 7 shared papers, 2016–2023 · strength 0.82
  4. Kosuke Mima · 5 shared papers, 2021–2024 · strength 0.76
  5. Rumi Itoyama · 3 shared papers, 2021–2024 · strength 0.47
  6. Zhao Liu · 3 shared papers, 2022–2023 · strength 0.44
  7. Takashi Matsumoto · 3 shared papers, 2021–2022 · strength 0.40
  8. Hideo Baba · 4 shared papers, 2016–2023 · strength 0.40
  9. Akira Chikamoto · 5 shared papers, 2016–2022 · strength 0.37
  10. Hirohisa Okabe · 3 shared papers, 2016–2024 · strength 0.31
  11. Chuan Lan · 2 shared papers, 2022–2023 · strength 0.31
  12. Yuki Kitano · 3 shared papers, 2016–2022 · strength 0.27
  13. Hideo Baba · 2 shared papers, 2021–2022 · strength 0.26
  14. Norio Uemura · 2 shared papers, 2021–2022 · strength 0.24
  15. Kazuki Matsumura · 2 shared papers, 2021–2022 · strength 0.24
  16. Fumimasa Kitamura · 2 shared papers, 2021–2022 · strength 0.24
  17. Kota Arima · 4 shared papers, 2016–2018 · strength 0.22
  18. Daisuke Hashimoto · 4 shared papers, 2016–2018 · strength 0.22
  19. Takashi Ofuchi · 1 shared paper, 2024 · strength 0.21
  20. Yuki Adachi · 1 shared paper, 2024 · strength 0.21
  21. Masayo Tsukamoto · 1 shared paper, 2023 · strength 0.17
  22. Hideo Baba · 1 shared paper, 2022 · strength 0.14
  23. Hiroki Sato · 1 shared paper, 2022 · strength 0.13
  24. Hideo Baba · 2 shared papers, 2016–2018 · strength 0.12
  25. Kensuke Yamamura · 2 shared papers, 2016–2018 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.